April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Insulin Like Growth Factor-1 As A Predicting Biomarker For Metastatic Uveal Melanoma In Humans
Author Affiliations & Notes
  • Vivian Barak
    Immunology Laboratory /Tumor Diagnosis,
    Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Ofira Zloto
    Ophthalmology,
    Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Jacob Pe'er
    Ophthalmology,
    Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Ina Kalickman
    Immunology Laboratory /Tumor Diagnosis,
    Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Shahar Frenkel
    Ophthalmology,
    Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Footnotes
    Commercial Relationships  Vivian Barak, None; Ofira Zloto, None; Jacob Pe'er, None; Ina Kalickman, None; Shahar Frenkel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1449. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vivian Barak, Ofira Zloto, Jacob Pe'er, Ina Kalickman, Shahar Frenkel; Insulin Like Growth Factor-1 As A Predicting Biomarker For Metastatic Uveal Melanoma In Humans. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1449.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : A number of studies have shown associations between high levels of Insulin like growth factor-1 receptor (IGF-1R) and metastatic Uveal Melanoma (UM). The purpose of this study was to examine the potential of IGF-1 in early detection of liver metastasis in patients with UM.

Methods: : Levels of serum IGF-1 were analyzed by ELISA (R&D Systems, Minneapolis, MN, USA) for 118 subjects in 3 different groups: 55 UM patients who did not develop metastasis within 10 years from diagnosis (DF), 22 metastatic patients, and 41 healthy subjects. Matched pairs univariate analysis was performed for the following 22 metastatic patients' serums: 12 and 6 months before the diagnosis of metastasis and at the day of diagnosis. The levels of the biomarker were compared between the control group, DF group and metastatic UM patients' group by using ANOVA and student t-test.

Results: : The mean±SD levels for the control, 10yDF, and metastatic groups were: 152.47±15.91, 115.18±13.78, and 96.31±21.59 ng/ml, respectively (p=0.0006). IGF-1 serum levels have been statistically significantly higher in the control group compared to both DF patients (p= 0.006) and metastatic UM patients (p=0.0003). In the matched pairs analysis the mean IGF-1 level increased from 12 months prior to diagnosis of liver metastasis to 6 months prior to diagnosis by 28.4% (p= 0.0193), and decreased from 6 months prior to diagnosis to the day of diagnosis by 10.7% (p=0.2435).

Conclusions: : IGF-1 levels in UM patients were significantly lower compared to healthy subjects. Therefore, there is an association between low levels of serum IGF-1 and UM. During the year prior to the metastatic diagnosis, IGF-1 levels did not change along a clear trend. Consequently, IGF-1 failed as a predictive marker for metastatic UM.

Keywords: melanoma • oncology • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×